Vascular Biogenics Ltd. (VBLT:NASDAQ) Annual Reports & Investor Relations Material

Overview

Vascular Biogenics Ltd, an Israeli-American biopharmaceutical firm, is dedicated to developing cutting-edge therapeutics for the treatment of major types of cancer and immune-inflammatory diseases. Among its innovative projects is VB-601, which employs monocyte targeting technology to tackle multiple inflammatory indications. Founded in 2000 under the name of Medicard Ltd, the company rebranded as Vascular Biogenics Ltd in January 2003. From its headquarters in Modi'in, Israel, Vascular Biogenics Ltd is poised to revolutionize the biopharmaceutical industry.

Annual Reports

Frequently Asked Questions

What is Vascular Biogenics Ltd.'s ticker?

Vascular Biogenics Ltd.'s ticker is VBLT

What exchange is Vascular Biogenics Ltd. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Vascular Biogenics Ltd.'s headquarters?

They are based in Modiin, Israel

How many employees does Vascular Biogenics Ltd. have?

There are 11-50 employees working at Vascular Biogenics Ltd.

What is Vascular Biogenics Ltd.'s website?

It is https://www.vblrx.com/

What type of sector is Vascular Biogenics Ltd.?

Vascular Biogenics Ltd. is in the Healthcare sector

What type of industry is Vascular Biogenics Ltd.?

Vascular Biogenics Ltd. is in the Biotechnology industry

Who are Vascular Biogenics Ltd.'s peers and competitors?

The following five companies are Vascular Biogenics Ltd.'s industry peers:

- CTI BioPharma

- Protagonist Therapeutics, Inc.

- Idera Pharmaceuticals, Inc.

- Sarepta Therapeutics

- Artelo Biosciences